ImmunoGen Unable To Ride Kadcyla Wave For Long; Disappoints Investors
This article was originally published in The Pink Sheet Daily
The biotech is fresh off the approval of a highly anticipated breast cancer treatment, which oncology powerhouse Roche/Genentech is commercializing, but investors are already shifting their focus to the company’s lead asset, which has been made riskier by the appearance of a safety signal in Phase II.
You may also be interested in...
ImmunoGen Hopes T-DM1 Hype Shines Light On Internal Efforts
The anticipated success of the recently filed T-DM1 has offered ImmunoGen the opportunity to shine a light on its own ADC efforts.
Buoyed By T-DM1 EMILIA Data, Roche Leaps To Early Breast Cancer Trial
In Phase III EMILIA study, Herceptin-containing antibody drug conjugate demonstrates three-month progression-free survival benefit, trend toward overall survival and, importantly, better safety profile. Results pave way for new trials in earlier disease using new FDA approval pathway.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.